Natera: A Buy As Positive Growth And Cashflow Outweigh Unprofitability
For my first rating of Natera, I called it a buy, while today's consensus seems to be between a hold and a strong buy. Both proven revenue growth and expected future growth outlooks are upside driv...
Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript
Natera, Inc. (NASDAQ:NTRA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Alexey Aleshin - GM of Oncology and ECD & Chief Medical Officer Michael B. Brophy - Chief...
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.3 per share a year ago.
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented...
Natera: The Clues In Q1 Earnings
Natera delivered stellar Q1 results, with revenue and EPS beating expectations, and strong volume growth, especially for its flagship Signatera product. Management sees significant upside for Signa...
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
AUSTIN, Texas,--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 s...
Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today released preliminary unaudited results for the fourth quarter and full year ...
Undercovered Dozen: Natera, Lloyds Banking Group, Eaton, Primoris Services +
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering diverse investment opportunities and encouraging discussion among investors. Ready Capital Corporation's new senior not...
Natera: Poised For A Great Future But I'd Wait For A Pullback
Natera, a leader in cfDNA testing, has shown impressive growth and is nearing profitability, but its current valuation appears overextended. The company's competitive landscape is intense, with riv...
Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardan...
Guardant Health Secures One of the Largest False Advertising Verdicts in History, Representing a Significant Victory for Colorectal Cancer Patients Who Could Benefit from Guardant Reveal™ Natera F...
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it has surpassed a key milestone with over 100 peer-reviewed ...
Natera, Inc. (NTRA) Q3 2024 Earnings Call Transcript
Natera, Inc. (NASDAQ:NTRA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 AM ET Company Participants Mike Brophy - CFO Steve Chapman - CEO Alexey Aleshin - GM Oncology, CMO Conference Cal...
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that new data from the GALAXY arm of the ongoing CIRCULATE-Japan trial w...
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced it will present new data on its personalized and tumor-informed mo...
Natera, Inc. (NTRA) Q1 2024 Earnings Call Transcript
Natera, Inc. (NASDAQ:NTRA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshke...
Related Companies